Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study

Lymph Node Metastasis Clinical Trial

— MA  

Official title:

Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05592925
• Other study ID #: FTian
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: October 31, 2022

Study information

• Verified date: October 2022
• Source: Shandong Provincial Hospital
• Contact: Feng Tian, Doctor
• Phone: 18866102886
• Email: tianfeng[@]sdu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We initially selected a total of 1128 patients with primary gastric cancer who presented at Shandong Provincial Hospital between January 2018 and October 2022, and retrospectively collected their clinical and pathological data. And retrospectively analyzed preoperative baseline characteristics, preoperative laboratory tests, and postoperative pathological results for these patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 516
• Est. completion date: October 31, 2022
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. patients with primary gastric malignant tumors,

2. patients who underwent radical resection of gastric cancer,

3. patients with a postoperative pathology of adenocarcinoma or signet ring cell carcinoma according to the WTO pathological classification,

Exclusion Criteria:

1. patients who have distant metastases, such as liver or lung metastases, were found on preoperative ultrasound and computed tomography (CT) examinations,

2. patients who have received preoperative neoadjuvant chemotherapy,

3. patients who take anticoagulant drugs (such as aspirin) prior to surgery,

4. patients who had any previous coagulation disorder.

Related Conditions & MeSH terms

• Gastric Cancer Stage
• Lymph Node Metastasis
• Lymphatic Metastasis
• Neoplasm Metastasis
• Stomach Neoplasms

Intervention

Diagnostic Test:
• coagulation-related factors
We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.

Locations

Country	Name	City	State
China	Shandong Provincial Hospital	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preoperative coagulation-related factors (MA values) of patients	MA values(mm). Measure the data of preoperative MA values in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.	Three years
Primary	Preoperative coagulation-related factors (platelet counts) of patients	Platelet counts(x10^9/L). Measure the data of preoperative platelet counts in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.	Three years
Primary	Preoperative coagulation-related factors (fibrinogen levels) of patients	Fibrinogen levels (g/L). Measure the data of preoperative fibrinogen levels in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.	Three years
Primary	Preoperative coagulation-related factors (D-dimer) of patients	D-dimer (mg/L). Measure the data of preoperative D-dimer in 516 gastric cancer patients to see wether this indicator correlated with tumor stage in patients with gastric cancer.	Three years
Primary	Postoperative pathological results of tumor T stage.	Recording the postoperative pathological tumor T stage in 516 patients with gastric cancer.	Three years
Primary	Postoperative pathological results of tumor N stage.	Recording the postoperative pathological tumor N stage in 516 patients with gastric cancer.	Three years.